Gain Therapeutics, Inc.

Gain Therapeutics, Inc. announced that its President and CEO, Gene Mack, will participate in a virtual fireside chat and one-on-one meetings at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit. The fireside chat is scheduled for Monday, June 15, 2026, with a replay available from 7:00 a.m. EDT. This event provides an opportunity for investors to engage with Gain's management and learn more about the company's clinical-stage pipeline, including its lead candidate GT-02287 for Parkinson's disease.

Gain Therapeutics disclosed positive interim clinical and biomarker data from Part 2 of its Phase 1b study of GT-02287 for Parkinson's disease. The data, presented at the 3rd International GBA1 Meeting 2026, supports continued development of the drug, showing an 81% average reduction in CSF GluSph and a 4.8-point difference in MDS-UPDRS scores for patients with elevated baseline GluSph. Participants also reported unsolicited perceived benefits, including improved sense of smell, taste, balance, gait, and sleep.

Gain Therapeutics reported a significant increase in net loss for Q1 2026, reaching $5.61 million, up from $4.53 million in the prior year. The company also disclosed substantial doubt about its ability to continue as a going concern beyond the first quarter of 2027, citing insufficient cash to fund operations. Operating expenses, including R&D and G&A, rose, while cash used in operating activities increased to $4.73 million.

Gain Therapeutics reported its financial results for the first quarter ended March 31, 2026, with a net loss of $0.13 per share, an improvement from $0.16 per share in the prior year. The company also provided a corporate update, highlighting promising biomarker and early clinical evidence from its ongoing Phase 1b study of GT-02287 for Parkinson's disease, including an 81% average decrease in GluSph levels and stable MDS-UPDRS scores. Gain Therapeutics anticipates FDA IND clearance for GT-02287 in Q2 2026 and expects to commence its Phase 2 study in Q3 2026.

Gain Therapeutics, Inc. announced its 2026 Annual Meeting of Stockholders will be held on Wednesday, June 24, 2026, at 8:30 a.m. Eastern time. Stockholders will vote on the election of seven director nominees and the ratification of Ernst & Young AG as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The record date for stockholders entitled to vote is April 27, 2026, with 42,654,038 shares outstanding.